These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 16268824

  • 1. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations.
    Shafran SD, Mashinter LD, Roberts SE.
    HIV Med; 2005 Nov; 6(6):421-5. PubMed ID: 16268824
    [Abstract] [Full Text] [Related]

  • 2. Lopinavir/ritonavir combination and total/HDL cholesterol ratio.
    Valerio L, Fontas E, Pradier C, Lavrut T, Garraffo R, Dunais B, Cua E, Dellamonica P.
    J Infect; 2005 Apr; 50(3):229-35. PubMed ID: 15780417
    [Abstract] [Full Text] [Related]

  • 3. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
    Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C, Dronda F, Antela A, Sanz J, Navas E, Miralles P, Berenguer J, Pérez S, Zapata A, González-García JJ, Peña JM, Vázquez JJ, Arribas JR.
    J Antimicrob Chemother; 2005 May; 55(5):800-4. PubMed ID: 15761071
    [Abstract] [Full Text] [Related]

  • 4. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
    Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Wirtz V, Rightmire A, Odeshoo L, McLaren C.
    AIDS; 2006 Mar 21; 20(5):711-8. PubMed ID: 16514301
    [Abstract] [Full Text] [Related]

  • 5. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
    Tomaka F, Lefebvre E, Sekar V, Van Baelen B, Vangeneugden T, Vandevoorde A, Diego Miralles G.
    HIV Med; 2009 May 21; 10(5):318-27. PubMed ID: 19210693
    [Abstract] [Full Text] [Related]

  • 6. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.
    Martínez E, Domingo P, Galindo MJ, Milinkovic A, Arroyo JA, Baldovi F, Larrousse M, León A, de Lazzari E, Gatell JM.
    Clin Infect Dis; 2004 Apr 01; 38(7):1017-23. PubMed ID: 15034836
    [Abstract] [Full Text] [Related]

  • 7. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.
    Pharmacotherapy; 2008 Mar 01; 28(3):323-30. PubMed ID: 18294112
    [Abstract] [Full Text] [Related]

  • 8. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J, TRIAD Study Group.
    J Antimicrob Chemother; 2009 Aug 01; 64(2):398-410. PubMed ID: 19515730
    [Abstract] [Full Text] [Related]

  • 9. Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults.
    Samaras K, Richardson R, Carr A.
    AIDS; 2010 Jul 17; 24(11):1727-31. PubMed ID: 20588105
    [Abstract] [Full Text] [Related]

  • 10. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC.
    Antivir Ther; 2005 Jul 17; 10(5):585-91. PubMed ID: 16152752
    [Abstract] [Full Text] [Related]

  • 11. [Effects of high-carbohydrate/low-fat diet on serum lipid ratios in healthy young subjects].
    Gan CF, Gong RR, Lin J, Li ZK, Tang H, Huang X, Li RH, Fang DZ.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Mar 17; 39(2):267-71, 275. PubMed ID: 18630700
    [Abstract] [Full Text] [Related]

  • 12. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S, Buclin T, Franc C, Guignard N, Khonkarly M, Tarr PE, Rochat B, Biollaz J, Telenti A, Decosterd LA, Cavassini M.
    Antivir Ther; 2006 Mar 17; 11(1):53-62. PubMed ID: 16518960
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.
    Shelton MJ, Wire MB, Lou Y, Adamkiewicz B, Min SS.
    Antimicrob Agents Chemother; 2006 Mar 17; 50(3):928-34. PubMed ID: 16495253
    [Abstract] [Full Text] [Related]

  • 14. [Postprandial changes of blood lipid after ordinary Chinese diet and the influencing factors thereof].
    Fu ZF, Liu ML.
    Zhonghua Yi Xue Za Zhi; 2009 Feb 03; 89(4):260-2. PubMed ID: 19552844
    [Abstract] [Full Text] [Related]

  • 15. The effects of coffee consumption on serum lipids and lipoprotein in healthy individuals.
    Onuegbu AJ, Agbedana EO.
    Afr J Med Med Sci; 2001 Feb 03; 30(1-2):43-5. PubMed ID: 14510149
    [Abstract] [Full Text] [Related]

  • 16. Serum lipid profiles including non-high density lipoprotein cholesterol levels in Turkish school-children.
    Uçar B, Kiliç Z, Dinleyici EC, Colak O, Güneş E.
    Anadolu Kardiyol Derg; 2007 Dec 03; 7(4):415-20. PubMed ID: 18065339
    [Abstract] [Full Text] [Related]

  • 17. The effect of Ramadan fasting on maternal serum lipids, cortisol levels and fetal development.
    Dikensoy E, Balat O, Cebesoy B, Ozkur A, Cicek H, Can G.
    Arch Gynecol Obstet; 2009 Feb 03; 279(2):119-23. PubMed ID: 18488237
    [Abstract] [Full Text] [Related]

  • 18. Factors associated with changes in serum total cholesterol levels over 7 years in middle-aged New Zealand men and women: a prospective study.
    Metcalf PA, Scragg RK, Swinburn BA, Shaw LM.
    Nutr Metab Cardiovasc Dis; 2001 Oct 03; 11(5):298-305. PubMed ID: 11887426
    [Abstract] [Full Text] [Related]

  • 19. Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project.
    De Socio GV, Bonfanti P, Ricci E, Orofino G, Madeddu G, Penco G, Gianelli E, Martinelli C, Carradori S, Quirino T, Rizzardini G, CISAI Study Group.
    Biomed Pharmacother; 2008 Jan 03; 62(1):16-20. PubMed ID: 17851026
    [Abstract] [Full Text] [Related]

  • 20. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, Burger D, Ruxrungtham K, Schutz M, Ananworanich J, HIV-NAT 017 Study Team.
    Pediatr Infect Dis J; 2008 Jul 03; 27(7):623-8. PubMed ID: 18520443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.